Preventing Diabetes.

About Us

Lifestyle diseases, caused by poor diet and physical inactivity among others, are rising rapidly worldwide. Each year 70% of all deaths globally – 40 million – are attributed to lifestyle diseases such as obesity, type 2 diabetes and heart disease.

Sigrid is a clinical-stage biotech Company driven by the vision to improve human health through material based innovations. We are pioneering a new class of engineered materials to prevent and treat lifestyle disease more safely and effectively.

SiPore15™ is a breakthrough medical device for the safe reduction of blood sugar levels in people at risk of developing diabetes, prediabetics, and newly diagnosed type 2 diabetics. The device is a tasteless and odourless white powder taken with water. Upon its approval, SiPore15™ will be the first treatment available for prediabetes, with the potential to prevent type 2 diabetes.

SiPore15™ is Sigrid Therapeutics’ lead product candidate in clinical development, originating from research at Stockholm University and Karolinska Institute.

Clinical Trials

We are currently planning our new clinical trial SHINE of our lead product candidate SiPore21™, the new and improved Sipore15™, formulated as a consumer-friendly solution for improvement in blood sugar levels in prediabetics and newly diagnosed type 2 diabetics.

Read more on our previous clinical trial STAR by clicking the link below.